Drug research and collaborations in China
As one of the first multinational companies to fund pharmaceutical research and development in China, GSK’s total R&D investment in China has exceeded RMB1 billion in the past 20 years. Research focus adheres to the disease control priorities set by Chinese government, such as infections, diabetes, oncology and respiratory diseases. Along with economic development and increased health care in China, GSK is planning to develop a more comprehensive and robust R&D strategy to bring China into a key strategic center for GSK global R&D in near future.
- We have established Clinical Research Centers in China with over 200 drug development projects conducted in collaboration with over 30 leading medical universities/hospitals.
- We are a clinical research leader in developing medicines for hepatitis, asthma, diabetes, oncology and mood disorders in China.
- Recently, we have further boosted our R&D investment in China with an emphasis on cancer prevention and treatment.
- We set up an OTC R&D organization in Tianjin in 2003 and a global R&D centre in Shanghai in 2007.
- Substantial investment is still dedicated to drug discovery and genetic research in leading medical universities and the Chinese Academy of Science. A collaboration program in the field of combinational chemistry with the Shanghai Institute of Materia Medica (SIMM) under China Academy of Sciences has continued for more than ten years.
From "made in China" to "discovered in China"
We set up a global R&D Centre in Shanghai in 2007. The new R&D centre in China will focus on research into neurodegeneration to create new medicines for such profound medical needs as multiple sclerosis, Parkinson's disease, and Alzheimer's disease.
The center will eventually direct the global discovery and development activities within its therapeutic area, from drug-target identification to late-stage clinical studies, while collaborating with research institutions elsewhere in China and other countries.
We are entering an exciting period of expansion for our R&D organization as it builds on the strength of the superb science now being conducted in China. We intend to be part of a future in which the phrase ‘discovered in China’ is heard as often as 'made in China' is heard today.